Vividion Therapeutics

Vividion Therapeutics is a biopharmaceutical company that operates as a wholly owned and independently operated subsidiary of Bayer AG. The company focuses on the development of small-molecule therapeutics for oncology and immunology indications. Its proprietary chemoproteomic platform technology allows for the identification of previously unknown, or "undruggable," protein targets, enabling the discovery of novel drugs.

The company's business model is centered on research and development, with a pipeline of candidates in various stages of preclinical and clinical development. Vividion collaborates with its parent company, Bayer, to advance its programs, benefiting from the larger company's resources and expertise while maintaining its operational independence. The company's revenue is primarily generated through milestone payments and royalties from its collaboration and licensing agreements.

Keywords: biopharmaceutical, small-molecule therapeutics, oncology, immunology, chemoproteomics, drug discovery, protein targets, clinical development, preclinical, licensing agreements